Yan Song, PhD

Vice President
Analysis Group, Boston, MA, USA

Poster(s):

• (300) Economic burden of recurrence in early-stage hepatocellular carcinoma (HCC) treated with curative intent: A retrospective analysis of SEER-Medicare data
  Wednesday, October 29, 2025

• (360) Real-World Clinical Outcomes and Disease Management Costs among High-Risk Non-Muscle Invasive Bladder Cancer Patients Treated with Bacillus Calmette-Guérin: A SEER-Medicare Analysis
  Wednesday, October 29, 2025